ACUTAAS

Acutaas Chemicals share price & financials

Price
₹3,246.2
Market cap
₹27.0k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 24 Jul 2026

Acutaas Chemicals Limited Q1 FY27

Revenue from Operations ₹329.7 cr +59%EBITDA ₹113.1 cr +100%EBITDA Margin 34.3% PAT ₹74.9 cr +70%

What went well

  • Revenue from operations reached INR 329.7 crores, representing 59.1% growth Y-o-Y.
  • Gross profit for the quarter was INR 190.9 crores, reflecting a 73% increase Y-o-Y, with gross margin expanding by 466 basis points to 57.9%.
  • EBITDA for the quarter was INR 113.1 crores, a more than twofold increase Y-o-Y, with EBITDA margin at 34.3%, up 973 basis points Y-o-Y.

What to watch

  • Specialty Chemicals segment revenue declined 10.6% Y-on-Y to INR 37 crores due to the strategic phasing out of commodity chemicals.
  • Other income for the quarter was INR 1.8 crores, significantly lower than INR 11 crores in the previous quarter due to reduced positive exchange fluctuation.
Read the full call →

What Acutaas Chemicals Limited does

Acutaas Chemicals Limited (formerly Ami Organics Limited), incorporated in 2007, is a Surat, Gujarat-based specialty and pharmaceutical intermediates manufacturer that has diversified into three reportable business segments — Semiconductor Chemicals, Battery Chemicals and Commodity Chemicals. It earns by producing and exporting advanced pharmaceutical intermediates, ultra-high-purity photoresist chemicals for semiconductor manufacturing, and battery electrolyte additives, alongside a broad base of over 30 established specialty chemicals (parabens, methyl salicylate and others) sold to cosmetics, agrochemical, coatings and industrial customers. The company runs four manufacturing units — Sachin, Ankleshwar and Jhagadia in Gujarat, and Greater Noida in Uttar Pradesh (operated under its Baba Fine Chemicals unit) — supported by an in-house R&D centre, and has built USFDA, PMDA and multiple ISO/GMP certifications across its facilities.

Segments

  • Semiconductor Chemicals
  • Battery Chemicals
  • Commodity Chemicals
Manufacturing facilities
4 (Sachin, Ankleshwar & Jhagadia, Gujarat; Greater Noida, Uttar Pradesh)
Total installed capacity
1,100 KL across the four plants
Reportable business segments
3 (Semiconductor Chemicals, Battery Chemicals, Commodity Chemicals)
Countries served
~55 (since inception)
Customer base
~600 clients, incl. 30+ relationships over a decade
Product breadth
610+ distinct products invoiced to customers in the last 5 years
Founded 2007Headquarters Surat, Gujarat, IndiaEmployees 879 (FY2024-25) Company website

Guidance record · Q1 FY27

what the last two calls moved 15 tracked 3 delivered 1 missed 11 open
  • Indichem JV Peak Revenue went quiet said Q4 FY26 Promised: ~1x capex (~INR 200 crores) Q1 FY27: The peak revenue target was not mentioned this quarter.
  • Electrolyte Additive Capex Completion delayed said Q3 FY25 Promised: H1 FY26 Q1 FY27: Phase 2 capex completion timeline pushed again, now expected by end of Q2 FY27.
  • FY26 Revenue Growth delivered said Q4 FY25 Promised: 25% growth Q4 FY26: Achieved 33% YoY growth for FY26, beating the revised guidance of ~30%.

All 15 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 56.3%, net profit up 68.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue244 271 304 206 305 +25%391 +44%422 +39%322 +56%
EBITDA48 67 84 51 97 +102%154 +130%181 +115%110 +116%
Net profit38 45 63 45 73 +92%112 +149%137 +117%76 +69%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +132.0% 1Y

₹1.5k₹2.0k₹2.5k₹3.0k₹3.5kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 17 Oct 2025Q3 FY26 — 28 Jan 2026Q4 FY26 — 30 Apr 2026Q1 FY27 — 24 Jul 2026

1Y: ₹1,458.3 on 10 Sept 2025 → ₹3,383.7. High ₹3,694.8 (3 Jul 2026), low ₹1,317.8 (30 Sept 2025).

How the price took the results

close before → close after

Q1 FY27
−5.8%
24 Jul
Q4 FY26
+3.7%
30 Apr
Q3 FY26
+7.8%
28 Jan
Q2 FY26
+6.0%
17 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 29.1% a year over 3 years, FY23 to FY26. Operating margin widened to 36.5%.

Year endingFY23FY24FY25FY26
Revenue₹616 Cr₹688 Cr₹990 Cr₹1.3k Cr
Operating profit₹123 Cr₹108 Cr₹225 Cr₹483 Cr
Operating margin20.0%15.7%22.7%36.5%
Interest₹2 Cr₹7 Cr₹5 Cr₹4 Cr
Depreciation₹12 Cr₹14 Cr₹25 Cr₹33 Cr
Net profit₹83 Cr₹44 Cr₹160 Cr₹367 Cr
Net margin13.5%6.4%16.2%27.7%
ROCE21.0%14.0%20.0%33.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹32 Cr₹36 Cr₹36 Cr₹37 Cr₹41 Cr₹41 Cr
Reserves₹132 Cr₹482 Cr₹550 Cr₹638 Cr₹1.4k Cr₹1.6k Cr
Borrowings₹137 Cr₹1 Cr₹3 Cr₹203 Cr₹8 Cr₹32 Cr
Other liabilities₹110 Cr₹136 Cr₹169 Cr₹193 Cr₹274 Cr₹235 Cr
Total liabilities₹410 Cr₹655 Cr₹759 Cr₹1.1k Cr₹1.7k Cr₹1.9k Cr
Fixed assets₹161 Cr₹178 Cr₹222 Cr₹357 Cr₹700 Cr₹601 Cr
Capital work in progress₹0 Cr₹3 Cr₹30 Cr₹125 Cr₹152 Cr₹228 Cr
Investments₹33 Cr₹33 Cr₹33 Cr₹68 Cr₹0 Cr₹118 Cr
Other assets₹216 Cr₹440 Cr₹474 Cr₹521 Cr₹843 Cr₹989 Cr
Total assets₹410 Cr₹655 Cr₹759 Cr₹1.1k Cr₹1.7k Cr₹1.9k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs added +4.67 pp while DIIs trimmed −2.83 pp. The shareholder count grew 5% to 1,25,569.

Promoters
32.7%
FIIs
21.6%
DIIs
19.6%
Government
0.0%
Public
26.2%

Since Jun 2025

  • FIIs +4.67 pp
  • DIIs −2.83 pp
  • Public −1.84 pp

How it drifted, 12 quarters

Over this window the public fell from 48.0% to 26.2% — −21.8 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 38.9%, FIIs 7.2%, DIIs 6.0%, Public 48.0%.Dec '23: Promoters 39.9%, FIIs 11.7%, DIIs 7.6%, Public 40.9%.Mar '24: Promoters 39.9%, FIIs 9.0%, DIIs 6.8%, Public 44.3%.Jun '24: Promoters 36.0%, FIIs 12.9%, DIIs 14.8%, Public 36.3%.Sep '24: Promoters 36.0%, FIIs 13.9%, DIIs 19.9%, Public 30.2%.Dec '24: Promoters 36.0%, FIIs 15.5%, DIIs 20.2%, Government 0.0%, Public 28.3%.Mar '25: Promoters 36.0%, FIIs 16.5%, DIIs 18.3%, Government 0.0%, Public 29.2%.Jun '25: Promoters 32.7%, FIIs 16.9%, DIIs 22.4%, Government 0.0%, Public 28.0%.Sep '25: Promoters 32.7%, FIIs 16.8%, DIIs 22.6%, Government 0.0%, Public 27.9%.Dec '25: Promoters 32.7%, FIIs 16.7%, DIIs 21.7%, Government 0.0%, Public 29.0%.Mar '26: Promoters 32.7%, FIIs 19.5%, DIIs 19.6%, Government 0.0%, Public 28.2%.Jun '26: Promoters 32.7%, FIIs 21.6%, DIIs 19.6%, Government 0.0%, Public 26.2%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Acutaas Chemicals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Nareshkumar Ramjibhai Patel 17.69%unchanged
Vaghasia Chetankumar Chhaganlal 14.97%unchanged
Government Pension Fund Global Sovereign3.54%unchanged
Kotak Mahindra Trustee Co Ltd A/C Kotak Multicap Fund Mutual fund3.53%−0.42 pp
Dhwani Girishkumar Chovatia 3.35%unchanged
SBI Healthcare Opportunities Fund Mutual fund2.35%+0.43 pp
Axis Max Life Insurance Limited A/C - Ulif01311/02/08lifehighgr104 - High Growth Fund Insurer2.19%unchanged
Vanaja Sundar Iyer 1.14%unchanged
Meenaben Vijaybhai Dayani 0.00%unchanged
Vijaybhai Gordhanbhai Dayani 0.00%unchanged
Zumbeshkumar R Patel 0.00%unchanged
Hirenkumar Vijayabhai Dayani 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in ACUTAAS

Filings to Aug 2026

0 new, 5 added, 2 trimmed, 0 sold out — net −2.17 L shares (−9.0%).

Held by funds
₹689 Cr
11 schemes
Biggest holder
SBI Healthcare Opportunities Fund
₹284 Cr · 4.9% of that fund
SchemeHoldingLast month
SBI Healthcare Opportunities Fund SBI Mutual Fund₹284 Crheld
SBI Smallcap Fund SBI Mutual Fund₹117 Crheld
HDFC Pharma and Healthcare Fund HDFC Mutual Fund₹105 Crheld
SBI Large and Midcap Fund SBI Mutual Fund₹79 Cr−2.20 L
SBI Innovative Opportunities Fund SBI Mutual Fund₹44 Crheld
Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund₹26 Cr+0.01 L
Nippon India Nifty 500 Momentum 50 Index Fund Nippon India Mutual Fund₹18 Cr+0.01 L
SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund₹13 Cr+0.00 L

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

5 added, 2 trimmed — net −2.17 L shares (−9.0%)

Funds are sitting on
+85%
vs est. average cost
Held by funds
₹689 Cr
11 schemes · ≈ 2.6% of the company
Biggest holder
SBI Healthcare Opportunities Fund
₹284 Cr · 4.9% of that fund

Shares held by these funds −36%

Apr '25 24.05 L shares Jul '26

What the price assumes

Attractive

To justify its price of ₹3384, this stock must grow earnings at 38% every year for 7 years. Our analysis caps realistic growth at ~54%. At that growth it is worth ₹6877 — upside of 103%.

Growth the price implies
38.1% a year
for 7 years, fading to 4%
It has actually compounded at
60.3% a year
net profit, FY23–FY26 · EPS 53.9%
The gap
-0.2 pp
103% downside if it only repeats history
Price today ₹3,383.7 Value at the reference growth ₹6,877.3

Change the assumptions yourself →

All earnings calls (6)

Read the Q1 FY27 call →

Learn to analyse Acutaas Chemicals Limited

Guides on how to read this kind of business and the numbers that matter.